Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 15;52(5):1801033.
doi: 10.1183/13993003.01033-2018. Print 2018 Nov.

ERS technical standard on bronchial challenge testing: pathophysiology and methodology of indirect airway challenge testing

Affiliations
Free article

ERS technical standard on bronchial challenge testing: pathophysiology and methodology of indirect airway challenge testing

Teal S Hallstrand et al. Eur Respir J. .
Free article

Abstract

Recently, this international task force reported the general considerations for bronchial challenge testing and the performance of the methacholine challenge test, a "direct" airway challenge test. Here, the task force provides an updated description of the pathophysiology and the methods to conduct indirect challenge tests. Because indirect challenge tests trigger airway narrowing through the activation of endogenous pathways that are involved in asthma, indirect challenge tests tend to be specific for asthma and reveal much about the biology of asthma, but may be less sensitive than direct tests for the detection of airway hyperresponsiveness. We provide recommendations for the conduct and interpretation of hyperpnoea challenge tests such as dry air exercise challenge and eucapnic voluntary hyperpnoea that provide a single strong stimulus for airway narrowing. This technical standard expands the recommendations to additional indirect tests such as hypertonic saline, mannitol and adenosine challenge that are incremental tests, but still retain characteristics of other indirect challenges. Assessment of airway hyperresponsiveness, with direct and indirect tests, are valuable tools to understand and to monitor airway function and to characterise the underlying asthma phenotype to guide therapy. The tests should be interpreted within the context of the clinical features of asthma.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: T.S. Hallstrand has nothing to disclose. Conflict of interest: J.D. Leuppi has nothing to disclose. Conflict of interest: G. Joos reports grants and personal fees for advisory board work and lecturing from AstraZeneca and Novartis, grants from Boehringer Ingelheim and Chiesi, grants and personal fees for advisory board work from GlaxoSmithKline, and personal fees for lecturing from Teva, outside the submitted work. Conflict of interest: G.L. Hall has nothing to disclose. Conflict of interest: K.H. Carlsen has nothing to disclose. Conflict of interest: D.A. Kaminsky has received honoraria for teaching at an annual Cardiorespiratory Diagnostics Course from MGC Diagnostics, Inc., outside the submitted work. Conflict of interest: A.L. Coates has nothing to disclose. Conflict of interest: D.W. Cockcroft is a member of a medical advisory board for Methapharm, as has received products for research purposes from Aerogen and Pharmaxis, outside the submitted work. Conflict of interest: B.H. Culver has nothing to disclose. Conflict of interest: Z. Diamant reports personal fees from Aerocrine, ALK, Aquilon, AstraZeneca, Boehringer Ingelheim, Gilead, HAL Allergy, MSD and Sanofi Genzyme-Regeneron, outside the submitted work. Conflict of interest: G.M. Gauvreau has nothing to disclose. Conflict of interest: I. Horvath reports personal fees and non-financial support from AstraZeneca, Berlin-Chemie, Chiesi, Boehringer Ingelheim, Novartis, CSL Behring and Roche, personal fees from Sandoz, GSK, Sager Pharma, Affidea, Orion Pharma and Teva, and non-financial support from MSD, outside the submitted work. Conflict of interest: F.H.C. de Jongh has nothing to disclose. Conflict of interest: B.L. Laube has nothing to disclose. Conflict of interest: P.J. Sterk has nothing to disclose. Conflict of interest: J. Wanger has nothing to disclose.